DIRS.INFO The most relevant business & tech news

☆ Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
▼ + stars: | 2023-12-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. Meanwhile, placebo-adjusted weight loss was 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks, Pfizer said. No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer's other discontinued weight loss pill.

Persons: Albert Bourla, Eli Lilly, danuglipron Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

☆ Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Compounding pharmacies prepare custom-made versions of commercially available treatments to meet the specific needs of a patient. Novo Nordisk first sued Brooksville Pharmaceuticals over copycat versions of Wegovy and Ozempic in July. Including the newest lawsuits, Novo Nordisk has filed 12 legal actions against compounding pharmacies, medical spas and weight loss clinics allegedly selling dupes of Wegovy and Ozempic. That puts patients "at risk of taking drug products that are less effective than expected based on their labeling," according to Novo Nordisk. Several states have also threatened to take legal action against compounding pharmacies that make or distribute unapproved variations of Novo Nordisk's weight loss treatments.

Persons: Eli Lilly, Jason Brett, Novo Organizations: Novo Nordisk, Wells Pharmacy Network, Brooksville Pharmaceuticals, Nordisk, Wells Pharmacy, Novo, U.S . Food, Drug Administration, FDA, CNBC PRO Locations: Oslo, Norway, Florida, U.S, Danish, Ozempic

☆ Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
▼ + stars: | 2023-11-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. The Danish drugmaker said it found impurities in all the drugs tested from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo said the compounded versions of Wegovy tested from Brooksville were also less potent than advertised, with one sample shown to be at least 19% weaker than indicated. The drugmaker has already filed 12 lawsuits against medical spas, weight-loss clinics and compounding pharmacies offering products that claim to contain semaglutide. The case against Wells was filed in the U.S. District Court, Middle District of Florida, Ocala division and the suit against Brooksville in U.S. District Court, Middle District of Florida, Tampa division.

Persons: Victoria Klesty, Danish drugmaker, Novo, Brooksville, ” Jason Brett, Eli Lilly, Mounjaro, Wells, Patrick Wingrove, Josephine Mason, Bill Berkrot, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wells Pharmacy, Brooksville Pharmaceuticals, U.S . Food, Drug Administration, FDA, Novo's, Middle District of, Brooksville, Thomson Locations: Oslo, Norway, Victoria, Danish, Florida, Wells, U.S, Middle District, Middle District of Florida, Ocala, Tampa

☆ Can a Big Pharma Ever Be Worth $1 Trillion?
▼ + stars: | 2023-11-29 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Daniel Skovronsky, chief scientific and medical officer at Eli Lilly, pushed the company to move more quickly and focus more on science. Photo: Maddie McGarvey for The Wall Street JournalThere are five tech companies valued at over $1 trillion. In healthcare, the closest contender is Eli Lilly . This year it became the first big pharmaceutical to surpass a market capitalization of $500 billion thanks to the popularity of its obesity and diabetes medications and, to a lesser extent, its experimental Alzheimer’s drug. But hanging over Lilly and rival Novo Nordisk is a reality that puts the brakes on big pharma’s ascent: the patent cliff.

Persons: Daniel Skovronsky, Eli Lilly, Maddie McGarvey, Lilly Organizations: Wall, Novo Nordisk

☆ GLP-1 weight loss drug boom to boost energy drink stocks, Lululemon, Stifel says
▼ + stars: | 2023-11-29 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Further uptake of the blockbuster weight loss drugs rocking the health-care world can bode well for select energy drink makers and fitness-focused retailers, Stifel said. Indeed, Stifel found an additional 21% said they would be interested in the drug if it showed proven results, was widely available and had approval from the U.S. Food and Drug Administration for weight loss specifically. Wegovy was approved to treat weight loss in 2022 and Eli Lilly's Zepbound recently received that same nod . These shifting food and health habits can also affect consumer spending — and stocks tied to specific retailers, Astrachan said. If half of those interested in GLP-1 drugs begin taking them, the firm expects U.S. energy drink consumption could increase about 2%.

Persons: bode, Stifel, Wegovy, Eli Lilly's Zepbound, Mark Astrachan, Astrachan, Atkins, Levi Strauss, Lululemon, — CNBC's Michael Bloom Organizations: Nordisk's Ozempic, U.S . Food, Drug Administration, Monster Beverage, Holdings, Food, BellRing Brands, Brands Locations: Stifel's U.S, U.S

☆ Investors spy value in cheap Finnish stocks after China and Russia pain
▼ + stars: | 2023-11-29 | by ( Danilo Masoni | ) www.reuters.com time to read: +4 min

Finnish stocks are Europe's biggest laggards this year, as risks stemming from tensions with Russia and concerns over China's stuttering recovery have hurt its exporters. The top 25 stocks in Helsinki are worth a combined $150 billion. The OMX Helsinki 25 (.OMXH25) has lost 10% this year, versus the STOXX 600's (.STOXX) 8% rally. "Finnish stocks are attractively valued and a lot of bad news is priced in," Alava said. "If the European economy recovers in 2024 as I expect, Finnish cyclical stocks should recover too... this could be a good time for long-term investors to increase holdings".

Persons: Finland's, Tomas Hildebrandt, EVLI, Hilderbrant, Hertta Alava, Henrik Ehrnrooth, Schindler, Nordea's Alava, LSEG, Danilo Masoni, Christina Fincher Organizations: OMX Helsinki, STOXX, Nordic, Novo Nordisk, Deutsche Bank, NATO, Russia, Zurich, Otis, Metsa Board, Thomson Locations: Russia, Helsinki, Finland, Europe, China, Ukraine, U.S, French, OMX Helsinki, Alava

☆ Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
▼ + stars: | 2023-11-28 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

Three of the people who took the suspected fake Ozempic did so to control their diabetes, while four took it for weight management, Karam said. People with diabetes need to closely manage their blood sugar, which can be done with a variety of medicines including Ozempic. Lebanon's Ministry of Public Health issued two recalls related to Ozempic in January 2023, according to its website. Karam said Ozempic is neither purchased nor provided by the Ministry of Public Health. Several people have been hospitalized in Austria for hypoglycemia after taking potentially fake versions of Ozempic.

Persons: Rita Karam, Eli Lilly's, Novo's, Karam, Ozempic, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Lebanese Ministry of Public Health, Lebanon's Ministry of Public Health, Novo Nordisk, World Obesity, Obesity, International Diabetes Federation, Ministry of Public Health, Reuters, Thomson Locations: Lebanon, Germany, Egypt, Russia, United States, Novo, Britain, Belgium, Austria

REUTERS/George Fre/File Photo Acquire Licensing RightsNov 27 (Reuters) - Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's (LLY.N) Mounjaro than those taking Novo Nordisk's (NOVOb.CO) popular rival weight loss drug, according to an analysis of health records and other data. After 3 months of treatment, patients on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic, the study also found. By 6 months, the difference had widened to 4.3%, and by 12 months, the Mounjaro group had lost an average of 7.2% more weight. An Eli Lilly spokesperson said the company does not promote or encourage the off-label use of any of its medicines, although its drug is now approved for weight loss. A trial is underway comparing the weight loss formulations of the two injected medicines in patients overweight or obese but without type 2 diabetes.

Persons: Lilly, George Fre, Eli Lilly's, Mounjaro, Eli Lilly, Nancy Lapid, Bill Berkrot Organizations: Novo Nordisk, Pharmacy, REUTERS, Novo, Thomson Locations: Provo , Utah, U.S

☆ Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
▼ + stars: | 2023-11-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or obese adults, according to a large analysis of real-world data published Monday. The results come as both drugs and similar treatments approved for weight loss soar in demand in the U.S. for their ability to help patients shed unwanted pounds over time. Previous head-to-head studies have similarly suggested that Mounjaro is more effective than Ozempic for weight loss and controlling blood sugar in adults with Type 2 diabetes. But Monday's study confirms Mounjaro's edge over Ozempic in a real-world setting, specifically among adults who are overweight or obese. Eli Lilly is pitting Mounjaro against Wegovy, a higher-dose version of Ozempic approved for weight loss, in an ongoing clinical trial in obese or overweight patients.

Persons: Eli Lilly, Mounjaro, We've, Nick Stucky Organizations: Novo Nordisk, Truveta Research, Research, Wegovy Locations: U.S

☆ Eli Lilly and Novo Nordisk will remain winners in the weight-loss category: Barclays' Emily Field
▼ + stars: | 2023-11-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain winners in the weight-loss category: Barclays' Emily FieldEmily Field, Barclays, joins 'Squawk Box' to discuss the latest news in the weight-loss drug market, the news to watch out for next year, and how investors should play the weight-loss drug market.

Persons: Eli Lilly, Emily, Emily Field Organizations: Novo Nordisk, Barclays

☆ Healthcare, AI and more: How one pro is investing for a 'Goldilocks' economy
▼ + stars: | 2023-11-24 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

A so-called Goldilocks economy is one which doesn't grow too quickly, or shrink too much — in other words, it's just right. "The reason they've such a high dividend yield is because there's something wrong with the company. And so, the value of the stock has gone down, which means the dividend yield is high," he said. And so, when, when I think about dividend stocks, I'm thinking about companies that pay a moderate dividend." Buy-rated stocks CNBC Pro screened for the top dividend stocks in each of the four themes Budden is looking at.

Persons: Andy Budden, it's, Budden, Eli Lilly, He's, Bard Organizations: Capital Group, U.S . Federal Reserve, CNBC Pro, Bank of America, Pharmaceutical, Novo Nordisk, Microsoft, Google

☆ Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
▼ + stars: | 2023-11-23 | by ( ) www.reuters.com time to read: +1 min

The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing RightsPARIS, Nov 23 (Reuters) - French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk (NOVOb.CO) in France, his office said, pitching it as a sign of newly restored French industrial competitiveness. The investment, for which no detail was provided by Macron's office, will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people. The Elysee palace deemed it the most significant investment in the health sector of Macron's mandates so far and said it would create 500 jobs. ($1 = 0.9168 euros)Reporting by Michel Rose, Editing by Dominique VidalonOur Standards: The Thomson Reuters Trust Principles.

Persons: Tom Little, Emmanuel Macron, Michel Rose, Dominique Vidalon Organizations: Novo Nordisk, REUTERS, Rights, Thomson Locations: Danish, Hillerod, Denmark, France, Chartres, Paris

Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsSummaryCompanies Novo racing to meet demand for obesity drugsObesity market to reach $100 billion by 2030-analystsNew investment in France will boost capacity for obesity, diabetes drugsPARIS/LONDON Nov 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Thursday announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand. There is a growing crisis in Europe over supply of diabetes therapy Ozempic, which uses the same ingredient semaglutide as the hugely popular weight-loss drug Wegovy, which is not yet widely available in Europe. Thursday's announcement comes after Novo earlier this month announced a $6 billion investment in its native Denmark to boost production. Analysts have estimated the obesity drug market will be worth as much as $100 billion by 2030.

Persons: Victoria Klesty, Danish drugmaker, Emmanuel Macron, Lars Fruergaard Jorgensen, Eli Lilly, Novo, Anna Ringstrom, Ludwig Burger, Terje Solsvik, David Goodman, Emelia Organizations: REUTERS, Novo Nordisk, WIN, French, Thomson Locations: Oslo, Norway, Victoria, France, PARIS, Chartres, Danish, Europe, Union, Germany, Belgium, Denmark, U.S, Paris

☆ Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
▼ + stars: | 2023-11-23 | by ( Jake Swearingen | ) www.businessinsider.com time to read: +2 min

Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. In the past two weeks, it's announced more than $8 billion in manufacturing investments. AdvertisementNovo Nordisk, maker of the popular anti-obesity drugs Ozempic and Wegovy, is investing billions to ramp up production capacity amid surging demand. The move comes just after Novo Nordisk unveiled plans to shell out over $6 billion to expand manufacturing capacity in Denmark. That money will go toward increasing production capacity for semaglutide, the key ingredient in Ozempic and related medications.

Persons: it's, —, Ozempic, Emmanuel Macron, Eli Lilly, David Ricks, Lilly, Goldman Sachs Organizations: Novo Nordisk, Service Locations: France, Chartres, Denmark, Europe, Novo

☆ These stocks have the most at risk as patients on Ozempic eat less, according to Morgan Stanley
▼ + stars: | 2023-11-23 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +3 min

The use of weight-loss drugs such as Ozempic is poised to change consumer consumption patterns, but not every food-related company will get hit in the same way, according to Morgan Stanley. Fast food restaurants were especially vulnerable. "Shoppers with obesity spend more at large fast food brands and, on a relative basis, less at fast casual restaurants and casual diners," Morgan Stanley said. One stock that is closer to a risky pure play is McDonald's , which is second highest on the list, according to the Morgan Stanley research. Low cost retailers like Walmart and snack and beverage companies like Pepsico are also exposed, according to the Morgan Stanley research.

Persons: Morgan Stanley, Eli Lilly, Pamela Kaufman, Kaufman, Tim Hortons, Burger, Taco Bell, — CNBC's Michael Bloom Organizations: Novo Nordisk, Denmark's Novo Nordisk, Restaurant Brands, Yum Brands, Walmart, Pepsico Locations: U.S

☆ Branding’s corporate titans face moment of truth
▼ + stars: | 2023-11-22 | by ( Aimee Donnellan | ) www.reuters.com time to read: +8 min

Now for the first time this century, sales volumes at the big consumer goods manufacturers are falling. In the first nine months of the year, Kraft Heinz said the quantity of its sold items declined by nearly 6 percentage points year-on-year. That’s likely to allow Nestlé, Kraft Heinz and Unilever to see flat or modest increases in 2023 sales, LSEG data shows. Earlier this year, outgoing Kraft Heinz Chief Executive Miguel Patricio said the company lost market share to a branded competitor that spent more. Unilever, Nestlé and Kraft Heinz have all pointed to a slowing of price growth in the coming year.

Persons: Kraft Heinz, Nestlé, ’, Xavier Roger, Kraft, what’s, John Furner, Miguel Patricio, Mars, ”, François, EY, George Hay, Streisand Neto, Thomas Shum Organizations: Reuters, Consumer, Kraft, Unilever, Danone, ’, United Nations, Reuters Graphics Reuters, Nestlé, Kraft Heinz, Target, Reuters Graphics, Obesity, Mondelez, Walmart, “, Thomson Locations: U.S, Europe, Australia, Norway, Chocolat, London

☆ VCs didn't care about OpenAI's weird board structure. It was all about investing in Sam Altman and its 'transformative' tech.
▼ + stars: | 2023-11-22 | by ( Madeline Renbarger | Vishal Persaud | ) www.businessinsider.com time to read: +5 min

OpenAI's venture capital investors weren't thinking about its mission to serve "humanity" by developing artificial intelligence. After Altman's ouster, Vinod Khosla, an early investor in OpenAI, came to his defense despite the criticism. OpenAI's complex and unique corporate governance structure meant that VCs could invest in the capped profit entity, but never earn any influence over the nonprofit board of directors, all of whom were either cofounders or appointed outside AI experts. The board structure and its governance are all likely to change as part of the deal to bring Sam Altman back as CEO of OpenAI. The purpose of the newly formed OpenAI board – consisting of current board member D'Angelo, former US Treasury Secretary Larry Summers, and former Salesforce co-CEO Bret Taylor – is to vet and potentially appoint an expanded board of up to nine people, and that Microsoft and Altman want board seats, The Verge reported.

Persons: Sam Altman, OpenAI, Altman, VCs, Sam, Altman's, Vinod Khosla, Yunus, Khosla, Wesley Chan, Greg Brockman, Ilya Sutskever, Tasha McCauley, who's, Joseph Gordon, Levitt, Helen Toner, Adam D'Angelo, Karthee Madasamy, it's, David Sacks, D'Angelo, Larry Summers, Bret Taylor – Organizations: Business, Tiger Global Management, Khosla Ventures, Sequoia Capital, Microsoft, FPV Ventures, Rand Corporation, Georgetown's Center for Security, Emerging Technology, MFV Partners, Qualcomm Ventures, Ikea, Bosch, Novo Nordisk Foundation, Bertelsmann Foundation, Carlsberg Foundation, Craft Ventures Locations: OpenAI, Silicon Valley, Hollywood

Handout via REUTERS/File photo Acquire Licensing RightsSummaryCompanies Ozempic shortages expected throughout 2024Victoza shortages expected until at least Q2 2024Diabetes drug Ozempic used 'off label' to treat obesityNov 21 (Reuters) - Novo Nordisk (NOVOb.CO) will ration starter kits of Ozempic in Europe and reduce supplies of another diabetes drug, Victoza, to prioritise producing Ozempic, which has seen a surge in demand from people using it to lose weight. Ozempic contains semaglutide, an ingredient in Novo's hugely popular anti-obesity drug Wegovy. Intermittent Ozempic shortages are expected throughout 2024, while Victoza shortages are expected at least until the second quarter of 2024, according to the statement on the EMA's website. "No new patients should be started on Victoza until at least Q2 2024 when supply is expected to normalise," Novo urged doctors in the document. It also told doctors to consider other injectable GLP-1 drugs or "other suitable alternatives" where Ozempic or Victoza are not available for patients.

Persons: Ozempic, hasn't, Novo, Eli Lilly's, tirzepatide, Ludwig Burger, Eva Mathews, Emelia Sithole, Mark Potter Organizations: Handout, REUTERS, Diabetes, Novo Nordisk, European Medicines Agency, EU, Thomson Locations: Novo, London, Britain, Europe, Danish, United States, France, Austria, Belgium, Germany, Wegovy, Norway, Denmark, EU

REUTERS/George Frey/File Photo Acquire Licensing RightsNov 21 (Reuters) - Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. The Tema Cardiovascular & Metabolic ETF (HRTS.O) invests in companies tackling diabetes, obesity and cardiovascular diseases, according to the New York-headquartered platform's website. The advances of the class of weight-loss and diabetes therapies known as GLP-1 receptor agonists, are only the tip of the iceberg, said David K. Song, investment partner and head of life sciences at Tema ETFs. The Tema fund has a net expense ratio of 0.75%. Reporting by Bansari Mayur Kamdar in Bengaluru; Editing by Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Lilly, George Frey, Eli Lilly, Mounjaro, David K, Morgan Stanley, Bansari Mayur, Emelia Sithole Organizations: Novo Nordisk, Pharmacy, REUTERS, Metabolic, Morgan Stanley Research, VanEck Pharmaceutical, Thomson Locations: Provo , Utah, U.S, Tema, Novo, New York, Bengaluru

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

☆ Cramer: Diversification is crushing investors this year. Will 2024 be different?
▼ + stars: | 2023-11-19 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

The stock of Club holding Morgan Stanley (MS) dropped to $70 from $100 before bouncing back to $80 when interest rates recently peaked. Morgan Stanley and Schwab did nothing bad or shameful, but their multiples are shadows of their former selves. At least Morgan Stanley has a nice dividend yield of 4.25%. Key, Huntington, First Horizon, Morgan Stanley and Schwab are all good franchises that are regarded as cheap. The Morgan Stanley headquarters is seen in New York City on Jan. 17, 2023.

Persons: It's, Huntington Bancshares, Stephen Steinour, Chris Gorman, Bryan Jordan, Morgan Stanley, That's, Charles Schwab, Schwab, We're, Macy's, Albert Bourla, Myers, Meyers, Eli Lilly, let's, Mills, Campbell Soup, WK Kellogg, McCormick, Neutrogena, Johnson, Edwards, Zimmer Biomet, Becton Dickenson, Baxter, BAX, Ford, Hess, Tesla, Jim Cramer's, Jim Cramer, Jim, Michael M Organizations: Dominion, Federal Reserve, Nordstrom, Pfizer, Bristol, Myers, Hostess Brands, Novo Nordisk, PepsiCo, Hershey, Brands, Spice, Johnson, Moderna, American Electric Power, Duke Energy, Motors, JetBlue, EOG Resources, ConocoPhillips, Exxon Mobil, Nvidia, Apple, Federal Trade Commission, CNBC, Santiago, Getty Locations: Huntington, Memphis, Tennessee, Toronto, United States, Celgene, Bristol, New York City

☆ Explainer: What’s behind the scramble for semaglutide?
▼ + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

Semaglutide, developed by Novo Nordisk (NOVOb.CO) over decades, is the active ingredient in type 2 diabetes treatments Ozempic and Rybelsus, as well as Wegovy, which is used for weight loss only. Semaglutide in injected form was first approved for use in the U.S. as a treatment for type 2 diabetes in 2017. Booming demand for both drugs has propelled Novo Nordisk to its highest-ever profits. People taking part in clinical trials for drugs based on semaglutide may also continue to take it. The curbs will be in force until August 2024, but may end sooner if supplies improve, a spokesperson for the health ministry said.

Persons: Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Josephine Mason, Sara Ledwith Organizations: Novo Nordisk, World Health Organization, International Diabetes Foundation, Supply, BMI, Thomson Locations: Britain, Germany, Belgium, United States, U.S, Denmark, Brussels

☆ Listen now: Who gets weight-loss drugs when supplies are tight?
▼ + stars: | 2023-11-18 | by ( ) www.reuters.com time to read: +1 min

Follow on Apple, Google or Spotify. Listen on the Reuters app. A revolutionary new class of drugs is transforming weight loss. But around the world, demand is skyrocketing for diabetes drugs because they also help people shed pounds. Join our global health journalists as we explore access to drugs like Wegovy and Ozempic and the transformation of the way we understand weight loss.

Persons: Lilly, Eli Lilly Organizations: Apple, Google, Reuters, Reading Novo Nordisk, Novo, Corporate America, Novo Nordisk, Thomson Locations: Belgium, Novo

☆ How well-off Brits still buy Ozempic online for weight loss
▼ + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com time to read: +12 min

NHS diabetes patients – including Gradwell, who went for weeks without full medication – pay nothing for their medication. The shortage persists even after Ozempic's manufacturer Novo Nordisk (NOVOb.CO) launched Wegovy, a semaglutide drug solely for weight loss, in September. Rightangled told Reuters it is within its rights to continue to prescribe Ozempic for weight loss. Two had stopped offering it for weight loss by October, but Rightangled continued to make it available as of Nov. 17, Reuters found. He said his oncologist said that while he could not prescribe Ozempic, it would be good for his health if he took it for weight loss.

Persons: Kim Gradwell, –, John, it's, Rightangled, Gradwell, Penny Ward, I've, Abdullah Sabyah, Ward, Juniper, Ben, Doctors, Novo, Ozempic, semaglutide, prescribers, Rightangled's Sabyah, Tyne wasn't, Gradwell's, Yaasir Mamoojee, We've, Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Chad Terhune, Sara Ledwith, Josephine Mason Organizations: Diabetes, National Health Service, Novo Nordisk, King's College, Department of Health, Social Care, John, Reuters, Oxford University ., NHS, Alliance Healthcare, Alliance, Diabetes UK, NICE, semaglutide, Oxford University, General Pharmaceutical Council, Tyne, Thomson Locations: Dudley , North Tyneside, Britain, Novo, United States, London, U.S, England, Europe, Ozempic, Newcastle, Brussels, Los Angeles

Search resuls for: "nordisk"

25 mentions found